ADMA Biologics, Inc. (ADMA) Stock Price & Analysis

ADMA Biologics, Inc. (ADMA) closed at USD 11.75 on Thursday, October 29, 2026, up 4.17% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 11.28; the Oct 29, 2026 session ranged USD 11.34–11.77 on volume of 2,742,126 shares. Market capitalization is $2.63B, with a 52-week range of USD 7.21–20.46 (NGM). Source: Nexqual, retrieved October 29, 2026 at 20:33 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ADMA.md

Key facts (ADMA)

• Last four reported quarters (through Jun 30, 2026): revenue $512M, net income $169M (33.0% margin), free cash flow $116M (SEC filings).
• Valuation: P/E 15.6x (avg 25.8x at the last 2 fiscal year-ends), EV/EBITDA 11.6x, net debt $60.6M.
• 1 of 80 tracked superinvestors hold ADMA (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
• Insider open-market purchases, last ~7 months: 3 Form 4 filings, $251K; 3 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 17 (range 12–21).
• Total return with dividends: 1Y -23.1% vs S&P 500 +14.4%; 5Y +810.9% vs S&P 500 +79.1%.
• Next earnings: 2026-11-04, EPS estimate USD 0.2, revenue estimate $138M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ADMA)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ADMA)

P/E 15.6x · P/S 5.1x · EV/EBITDA 11.6x · EV/Sales 5.3x · P/FCF 22.6x · P/B 6.5x · FCF yield 4.43% · Earnings yield 6.42% · Buyback yield (TTM) 7.11% · Net debt $60.6M · EV $2.69B

P/E at fiscal year-ends: Dec 2025 30.4x, Dec 2024 21.1x.

Superinvestors (SEC 13F-HR, Q2 2026) (ADMA)

1 of 80 tracked investors hold ADMA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider purchases (SEC Form 4, open-market, last ~7 months) (ADMA)

3 purchases, $251K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ADMA)

Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 17 (low 12, high 21).

Rating changes, last 120 days:

Total return (dividends reinvested) (ADMA)

ADMA earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ADMA recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ADMA revenue by business segment (quarter ended Jun 30, 2026)

ADMA revenue by product line (quarter ended Jun 30, 2026)

ADMA revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

ADMA suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

ADMA analyst estimates and revisions

ADMA options: expected move

Options price a move of about ±18.8% (±$2.13) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±7.7% on average.

30-day implied volatility 65% vs 38.9% realized over the last 30 trading days. Put/call ratio (volume) 0.39. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 20:33 UTC)

Technical Analysis (ADMA)

Nexqual's technical model rates ADMA "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 20:33 UTC.

Analyst Ratings (ADMA)

Wall Street analysts rate ADMA "Buy" based on 4 analysts, with a mean price target of USD 17 (range USD 12–21), per Nexqual as of October 29, 2026 at 20:33 UTC.

Earnings (ADMA)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 20:33 UTC.

Financials & Fundamentals (ADMA)

Source: Nexqual, October 29, 2026 at 20:33 UTC.

Financial Health Score (ADMA)

Nexqual rates ADMA Biologics, Inc.'s overall financial health "Strong" across five dimensions, as of October 29, 2026 at 20:33 UTC.

Ownership (ADMA)

Source: Nexqual, October 29, 2026 at 20:33 UTC.

Leadership (ADMA)

ADMA Biologics, Inc. is led by Adam S. Grossman, Co-Founder, President, CEO & Director, per Nexqual as of October 29, 2026 at 20:33 UTC.

Major Backers & Investors (ADMA)

Notable institutional backers of ADMA Biologics, Inc. include First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd., Rubric Capital Management LP, Capital Group, according to Nexqual as of October 29, 2026 at 20:33 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 20:33 UTC.

From ADMA Biologics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• The end-to-end production cycle can take approximately seven to 12 months for a batch of FDA released drug product.
• In June 2025, we filed our supplemental Biologics License Application ("sBLA") for the expansion of ASCENIV's label to include the pediatric setting for patients who are two years and older and we anticipate potential FDA approval of the sBLA in the first half of fiscal year 2026.
• We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
• We anticipate submitting a pre-Investigational New Drug (IND) package to the FDA in fiscal year 2026, which could enable us to progress development of SG-001 directly into a registrational clinical trial.

Partnerships

• Effective October 1, 2024, we entered into an Amended and Restated Plasma Purchase Agreement with Grifols (the "A&R Grifols Agreement") with a term expiring in September 2039, after which it may be renewed for two additional multi-year periods if agreed to by the parties.
• Effective August 6, 2024, we entered into a Plasma Purchase Agreement with KEDPlasma LLC ("KEDPlasma") with a term expiring in July 2031, after which it may be renewed for an additional multi-year period if agreed to by the parties (the "KEDPlasma Agreement").

Legal & Regulatory Risks (Item 1A, quoted)

• Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the market and we could be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.
• Our ADMA BioCenters operations collect information from donors in the United States that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their requirements.
• We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:33 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt